Andrew Komjathy - Feb 8, 2024 Form 4 Insider Report for Astria Therapeutics, Inc. (ATXS)

Role
Chief Commercial Officer
Signature
/s/ Noah Clauser, as attorney-in-fact for Andrew Komjathy
Stock symbol
ATXS
Transactions as of
Feb 8, 2024
Transactions value $
$0
Form type
4
Date filed
2/12/2024, 04:05 PM
Previous filing
Jun 6, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATXS Stock Option (Right to Buy) Award $0 +175K $0.00 175K Feb 8, 2024 Common Stock 175K $15.26 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on February 8, 2024 and is subject to vesting over a four-year period, with 25% of the 175,000 shares underlying the option upon grant vesting on the first anniversary of February 8, 2024 and the remainder vesting over the ensuing three years in equal monthly installments.